Results 31 to 40 of about 177,089 (78)

Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2019
Significance RAS genes are among the most mutated proto-oncogenes in human cancer. The mechanisms supporting RAS transformation are not fully understood, particularly regarding the relative contributions of oxidant versus antioxidant pathways.
Jonathan K. M. Lim   +11 more
semanticscholar   +1 more source

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

open access: yesNature, 2017
Approximately 200 BRAF mutant alleles have been identified in human tumours. Activating BRAF mutants cause feedback inhibition of GTP-bound RAS, are RAS-independent and signal either as active monomers (class 1) or constitutively active dimers (class 2).
Z. Yao   +18 more
semanticscholar   +1 more source

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

open access: yesPLoS Biology, 2008
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress.
Jean-Philippe Coppé   +8 more
semanticscholar   +1 more source

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

open access: yesNature, 2013
Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally associated with poor response to standard therapies. Efforts to target this oncogene directly have faced difficulties owing to its
J. Ostrem   +4 more
semanticscholar   +1 more source

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

open access: yesNature Cell Biology, 2018
Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAFV600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other
R. Nichols   +22 more
semanticscholar   +1 more source

A Comparative Analysis of Individual RAS Mutations in Cancer Biology

open access: yesFrontiers in Oncology, 2019
In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode four highly homologous proteins. RAS proteins are small GTPases involved in a broad spectrum of key molecular and cellular activities, including proliferation and ...
Carmen Muñoz-Maldonado   +2 more
semanticscholar   +1 more source

Siwalik plant megafossil diversity in the Eastern Himalayas: A review. [PDF]

open access: yesPlant Divers, 2023
Khan MA   +6 more
europepmc   +1 more source

Phylogenomic inference of the African tribe Monodoreae (Annonaceae) and taxonomic revision of Dennettia, Uvariodendron and Uvariopsis. [PDF]

open access: yesPhytoKeys, 2023
Dagallier LMJ   +8 more
europepmc   +1 more source

Ras-Mediated Activation of the Raf Family Kinases

open access: yesCold Spring Harbor Perspectives in Medicine, 2019
The extracellular signal-regulated kinase (ERK) cascade comprised of the Raf, MEK, and ERK protein kinases constitutes a key effector cascade used by the Ras GTPases to relay signals regulating cell growth, survival, proliferation, and differentiation ...
Elizabeth M. Terrell, D. Morrison
semanticscholar   +1 more source

RAS: Striking at the Core of the Oncogenic Circuitry

open access: yesFrontiers in Oncology, 2019
Cancer is a devastating disease process that touches the lives of millions worldwide. Despite advances in our understanding of the genomic architecture of cancers and the mechanisms that underlie cancer development, a great therapeutic challenge remains.
R. Gimple, Xiuxing Wang
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy